Maxim Biomedical Gains New Minority Investment Partner and New CEO

Maxim Biomedical, one of the leading end-to-end rapid diagnostic test developers and manufacturers has received a new minority investment from CTM Investments. This sparks a new shift for the company.

 

CTM Investments is a growth equity vehicle led by Jason Gray focused on investing in companies that matter and enabling businesses to achieve important goals for their customers, employees, communities, and owners.  Jason Gray serves as Head of Investment Team at Pritzker Vlock Capital Management (PVCM).  

 

With this company shift, Jonathan Maa is transitioning from the role of Chief Operating Officer to the role of Chief Executive Officer. Previous Chief Executive Officer and Co-Founder Dr. Joe Maa will transition to the role of Chief Scientific Officer.

 

Johnathan Maa said, “It is my honor to now serve as MaximBio’s CEO. We are proud to partner with some of the world’s leading healthcare companies and government agencies to deliver diagnostic tests for many of the world’s most pressing indications. My goal in bringing on our new investment partners and in assuming the role of CEO is all about positioning MaximBio to leverage our core platform to serve our mission of improving patient outcomes.”

 

“We are passionate about companies that matter, about excellently run businesses, and about growth — and MaximBio has all three. We admire the long history of MaximBio and look forward to partnering with Jonathan and the team to support the company’s business going forward,” said investor Jason Gray.

 

Johnathan Maa continued, “Our history is marked by innovation and excellence, from the early days of HIV diagnostic testing to our recent achievements in rapidly scaling up COVID test manufacturing and providing millions of tests in response to the pandemic. We are committed to building on this legacy in IVD development and manufacturing for years to come.”